INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE HEMISPHERIC STROKE - THE EUROPEAN COOPERATIVE ACUTE STROKESTUDY (ECASS)
W. Hacke et al., INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE HEMISPHERIC STROKE - THE EUROPEAN COOPERATIVE ACUTE STROKESTUDY (ECASS), JAMA, the journal of the American Medical Association, 274(13), 1995, pp. 1017-1025
Objective.-To evaluate the efficacy and safety of intravenous thrombol
ysis using recombinant tissue plasminogen activator (rt-PA) in patient
s with acute ischemic stroke. Design.-Randomized, prospective, multice
nter, double-blind, placebo-controlled clinical trial. Setting.-A tota
l of 75 hospitals in 14 European countries. Patients.-A total of 620 p
atients with acute ischemic hemispheric stroke and moderate to severe
neurologic deficit and without major early infarct signs on initial co
mputed tomography (CT). Intervention.-Patients were randomized to trea
tment with 1.1 mg per kilogram of body weight of rt-PA (alteplase) or
placebo within 6 hours from the onset of symptoms. Outcome Measures.-P
rimary end points included Barthel Index (BI) and modified Rankin Scal
e (RS) at 90 days. Secondary end points included combined BI and RS, S
candinavian Stroke Scale (SSS) at 90 days, and 30-day mortality. Terti
ary end points included early neurologic recovery (SSS) and duration o
f in-hospital stay. Safety parameters included mortality and incidence
of intracranial or extracranial hemorrhage. Results.-The distribution
of demographic variables was similar among patients in the rt-PA and
placebo treatment arms in both the intention-to-treat (ITT) analysis a
nd the explanatory analysis for the target population (TP). A total of
109 patients (17.4%) were included in the trial despite major protoco
l violations but excluded from the TP. There was no difference in the
primary end points in the ITT analysis, while the TP analysis revealed
a significant difference in the RS in favor of rt-PA-treated patients
(P=.035). Of the secondary end points, the combined BI and RS showed
a difference in favor of rt-PA-treated patients in both analyses (P<.0
01). Neurologic recovery at 90 days was significantly better for rt-PA
-treated patients in the TP (P=.03). The speed of neurologic recovery
assessed by the SSS was significantly better up to 7 days in the ITT a
nalysis and up to 30 days for the TP in the rt-PA treatment arm. In-ho
spital stay was significantly shorter in the rt-PA treatment arm in bo
th analyses. There were no statistically significant differences in th
e mortality rate at 30 days or in the overall incidence of intracerebr
al hemorrhages among the rt-PA and placebo treatment arms in either an
alysis. However, the occurrence of large parenchymal hemorrhages was s
ignificantly more frequent in the rt-PA-treated patients. Conclusions.
-Intravenous thrombolysis in acute ischemic stroke is effective in imp
roving some functional measures and neurologic outcome in a defined su
bgroup of stroke patients with moderate to severe neurologic deficit a
nd without extended infarct signs on the initial CT scan. However, the
identification of this subgroup is difficult and depends on recogniti
on of early major CT signs of early infarction. Therefore, since treat
ing ineligible patients is associated with an unacceptable increase of
hemorrhagic complications and death, intravenous thrombolysis cannot
currently be recommended for use in an unselected population of acute
ischemic stroke patients.